Itepekimab

• Description :

  Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) [1][2][3][4].

• Product Name Alternative :

  REGN-3500; SAR-440340

• UNSPSC :

  12352203

• Target :

  Interleukin Related; NF-κB

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation; NF-κB

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/itepekimab.html

• Purity :

  99.40

• Solubility :

  10 mM in DMSO

• Smiles :

  [Itepekimab]

• Molecular Weight :

  (144.64 kDa)

• References & Citations :

  [1]Wechsler ME, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385 (18) :1656-1668.|[2]Kosloski MP, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15 (2) :384-395.|[3]Rabe KF, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9 (11) :1288-1298.|[4]Asrat S, et al. Itepekimab Binds to IL-33 With High Affinity, Prevents the Formation of IL-33/ST2/IL-1RAcP Signaling Complex and Blocks Mediators of Airway Inflammation[M]//C13. CYTOKINES: CYTOKINES IN THE AIRWAYS. American Thoracic Society, 2023: A4478-A4478.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [2226742-52-3]